Kyowa Kirin Co., Ltd.
4151.TDrugs in Pipeline
61
Phase 3 Programs
32
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Cinacalcet Hydrochloride
Secondary Hyperparathyroidism
Istradefylline (KW-6002)
Parkinson's Disease
KHK4827
Moderate to Severe Systemic Sclerosis
KHK4827 140mg SC
Psoriasis Vulgaris
OPC-262
Type 2 Diabetes
Antithrombin gamma
Preeclampsia
KHK7791
Hyperphosphatemia
KRN23
X-linked Hypophosphatemia
Istradefylline 20 mg or 40 mg
Idiopathic Parkinson's Disease
AMG 531
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
OPC-262 2.5 mg
Diabetes Type 2
darbepoetin alfa
Anemia
KW-6500
Parkinson's Disease
KW-2246
Cancer Related Pain (Breakthrough Pain)
Istradefylline
Parkinson's Disease
KW-2246 (fentanyl citrate)
Pain, Cancer
KHK7580
Secondary Hyperparathyroidism
EN3267
Pain
KW-3357
Disseminated Intravascular Coagulation (DIC)
Istradefylline 40 mg
Idiopathic Parkinson's Disease
saxaglipitin
Diabetes
Granisetron
Chemotherapy-induced Nausea and Vomiting
KK8398
Achondroplasia
ARQ197
Liver Cancer
Romiplostim
Aplastic Anemia
Brodalumab
Axial Spondyloarthritis
Istradefylline ( KW-6002)
Parkinson's Disease
Humira®
Arthritis, Rheumatoid
FKB327
Arthritis, Rheumatoid
burosumab
X-linked Hypophosphatemia
Cinacalcet HCl
Parathyroid Carcinoma
KRN1493
Secondary Hyperparathyroidism
KHK6188
Postherpetic Neuralgia
benralizumab
Eosinophilic Chronic Rhinosinusitis
RTA 402
Chronic Kidney Disease
Entinostat
Advanced or Recurrent Breast Cancer
KHK7580 low dose
Secondary Hyperparathyroidism
KHK4951
Neovascular Age-Related Macular Degeneration (nAMD)
ME-401
Indolent B-cell Non-Hodgkin's Lymphoma
VCAP/AMP/VECP(mLSG15)
Adult T-cell Leukemia-Lymphoma
KW-0761
Peripheral T/NK-cell Lymphoma
Aflibercept Injection
Diabetic Macular Edema (DME)
ziftomenib
Acute Myeloid Leukemia (AML)
KW-0761 (mogamulizumab)
Peripheral T-Cell Lymphoma
KK8123
X-linked Hypophosphatemia
KHK4577
Atopic Dermatitis
KHK4563
Uncontrolled and Suspected Eosinophilic Asthma
KRN125(pegfilgrastim), PLR001(plerixafor)
Multiple Myeloma and Malignant Lymphoma
KW-6356
Parkinson's Disease
Romiplostim (AMG-531)
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
AMG531
Aplastic Anemia
pegfilgrastim
Neutropenia
KW-2478
Multiple Myeloma
KRN321
MDS
Placebp
Hyperphosphatemia
ARQ 197
Gastric Cancer
saxagliptin
Diabetes, Type 2
KK2430
Hematologic Neoplasms
Pralatrexate
Adult T-cell Leukemia-Lymphoma
KHK4083
Ulcerative Colitis
apomorphine hydrochloride
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cinacalcet Hydrochloride | Phase 3 | Secondary Hyperparathyroidism | - | - |
Istradefylline (KW-6002) | Phase 3 | Parkinson's Disease | - | - |
KHK4827 | Phase 3 | Moderate to Severe Systemic Sclerosis | - | - |
KHK4827 140mg SC | Phase 3 | Psoriasis Vulgaris | - | - |
OPC-262 | Phase 3 | Type 2 Diabetes | - | - |
Antithrombin gamma | Phase 3 | Preeclampsia | - | - |
KHK7791 | Phase 3 | Hyperphosphatemia | - | - |
KRN23 | Phase 3 | X-linked Hypophosphatemia | - | - |
Istradefylline 20 mg or 40 mg | Phase 3 | Idiopathic Parkinson's Disease | - | - |
AMG 531 | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | - | - |
OPC-262 2.5 mg | Phase 3 | Diabetes Type 2 | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
KW-6500 | Phase 3 | Parkinson's Disease | - | - |
KW-2246 | Phase 3 | Cancer Related Pain (Breakthrough Pain) | - | - |
Istradefylline | Phase 3 | Parkinson's Disease | - | - |
KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer | - | - |
KHK7580 | Phase 3 | Secondary Hyperparathyroidism | - | - |
EN3267 | Phase 3 | Pain | - | - |
KW-3357 | Phase 3 | Disseminated Intravascular Coagulation (DIC) | - | - |
Istradefylline 40 mg | Phase 3 | Idiopathic Parkinson's Disease | - | - |
saxaglipitin | Phase 3 | Diabetes | - | - |
Granisetron | Phase 3 | Chemotherapy-induced Nausea and Vomiting | - | - |
KK8398 | Phase 3 | Achondroplasia | - | - |
ARQ197 | Phase 3 | Liver Cancer | - | - |
Romiplostim | Phase 3 | Aplastic Anemia | - | - |
Brodalumab | Phase 3 | Axial Spondyloarthritis | - | - |
Istradefylline ( KW-6002) | Phase 3 | Parkinson's Disease | - | - |
Humira® | Phase 3 | Arthritis, Rheumatoid | - | - |
FKB327 | Phase 3 | Arthritis, Rheumatoid | - | - |
burosumab | Phase 3 | X-linked Hypophosphatemia | - | - |
Cinacalcet HCl | Phase 3 | Parathyroid Carcinoma | - | - |
KRN1493 | Phase 3 | Secondary Hyperparathyroidism | - | - |
KHK6188 | Phase 2 | Postherpetic Neuralgia | - | - |
benralizumab | Phase 2 | Eosinophilic Chronic Rhinosinusitis | - | - |
RTA 402 | Phase 2 | Chronic Kidney Disease | - | - |
Entinostat | Phase 2 | Advanced or Recurrent Breast Cancer | - | - |
KHK7580 low dose | Phase 2 | Secondary Hyperparathyroidism | - | - |
KHK4951 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
ME-401 | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma | - | - |
VCAP/AMP/VECP(mLSG15) | Phase 2 | Adult T-cell Leukemia-Lymphoma | - | - |
KW-0761 | Phase 2 | Peripheral T/NK-cell Lymphoma | - | - |
Aflibercept Injection | Phase 2 | Diabetic Macular Edema (DME) | - | - |
ziftomenib | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
KW-0761 (mogamulizumab) | Phase 2 | Peripheral T-Cell Lymphoma | - | - |
KK8123 | Phase 2 | X-linked Hypophosphatemia | - | - |
KHK4577 | Phase 2 | Atopic Dermatitis | - | - |
KHK4563 | Phase 2 | Uncontrolled and Suspected Eosinophilic Asthma | - | - |
KRN125(pegfilgrastim), PLR001(plerixafor) | Phase 2 | Multiple Myeloma and Malignant Lymphoma | - | - |
KW-6356 | Phase 2 | Parkinson's Disease | - | - |
Romiplostim (AMG-531) | Phase 2 | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | - | - |
AMG531 | Phase 2 | Aplastic Anemia | - | - |
pegfilgrastim | Phase 2 | Neutropenia | - | - |
KW-2478 | Phase 2 | Multiple Myeloma | - | - |
KRN321 | Phase 2 | MDS | - | - |
Placebp | Phase 2 | Hyperphosphatemia | - | - |
ARQ 197 | Phase 2 | Gastric Cancer | - | - |
saxagliptin | Phase 2 | Diabetes, Type 2 | - | - |
KK2430 | Phase 2 | Hematologic Neoplasms | - | - |
Pralatrexate | Phase 2 | Adult T-cell Leukemia-Lymphoma | - | - |
KHK4083 | Phase 2 | Ulcerative Colitis | - | - |
apomorphine hydrochloride | Phase 2 | Parkinson's Disease | - | - |
Postherpetic Neuralgia
1 drug in this indication
Ulcerative Colitis
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Advanced or Recurrent Breast Cancer
1 drug in this indication
Secondary Hyperparathyroidism
1 drug in this indication
Parathyroid Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kyowa Kirin Co., Ltd.'s drug pipeline?→
CatalystAlert tracks 61 drug candidates in Kyowa Kirin Co., Ltd.'s (4151.T) pipeline across Phase 3, Phase 2. Its lead program is Cinacalcet Hydrochloride (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kyowa Kirin Co., Ltd.'s next FDA catalyst?→
Kyowa Kirin Co., Ltd.'s (4151.T) next tracked catalyst is a Phase 2 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track 4151.T biotech catalysts?→
Add 4151.T to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kyowa Kirin Co., Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.